中信建投（601066）证券(06066)发布公告，中信建投证券股份有限公司2025年面向专业投资者公开发 行永续次级债券(第六期)发行规模不超过30亿元(含30亿元)。本期债券发行工作已于2025年11月20日结 束。本期债券(债券简称：25信投Y6，代码：244197)实际发行规模22亿元，最终票面利率为2.25%，认 购倍数为1.9136。 ...

智通财经APP讯，中信建投证券(06066)发布公告，中信建投证券股份有限公司2025年面向专业投资者公 开发行永续次级债券(第六期)发行规模不超过30亿元(含30亿元)。本期债券发行工作已于2025年11月20 日结束。本期债券(债券简称：25信投Y6，代码：244197)实际发行规模22亿元，最终票面利率为 2.25%，认购倍数为1.9136。 ...

格隆汇11月20日丨中信建投证券(06066.HK)公告，根据《中信建投证券股份有限公司2025年面向专业投 资者公开发行永续次级债券(第六期)发行公告》，中信建投证券股份有限公司2025年面向专业投资者公 开发行永续次级债券(第六期)(以下简称"本期债券")以每5个计息年度为1个重定价周期，在每个重定价 周期末，发行人有权选择将本期债券期限延长1个重定价周期(即延续5年)，或全额兑付本期债券。 本期债券发行规模不超过30亿元(含30亿元)。本期债券发行工作已于2025年11月20日结束。本期债券(债 券简称：25信投Y6，代码：244197)实际发行规模22亿元，最终票面利率为2.25%，认购倍数为1.9136。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 经中国证券监督管理委员会"证监许可〔2025〕1336号"文注册， 中信建投证券股份有限公司（以下简称"发行人"）获准向专业投资 者公开发行面值不超过人民币200亿元（含200亿元）的永续次级公司 债券。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6066） 海外監管公告 本 公 告 乃 中 信 建 投 証 券 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 之《中 信 建 投 証 券 股 份 有 限 公 司2025年 面 向 專 業 投 資 者 公 開 發 行 永 續 次 級 債 券（第 六 期）發 行 結 果 公 告》，僅 供 參 閱。 承董事會命 中信建投証券股份有限公 ...

Core Viewpoint - Multiple brokerages are optimistic about China's economy in 2026, expecting it to maintain resilience and enter a phase of high-quality development, with the A-share market continuing its upward trend, although some predict a slowdown in growth [1][3][5]. Economic Outlook - The first three quarters of 2023 showed steady progress in China's economy, with expectations that 2026 will mark the beginning of a new high-quality development phase [3]. - Macro policies are anticipated to shift from extraordinary counter-cyclical adjustments to a more normalized approach, focusing on technological self-reliance and the cultivation of new productive forces [3]. - External demand is expected to remain resilient, while internal demand will rely on fiscal efforts to boost investment in human capital and consumer supply [3]. A-share Market Trends - Since 2025, the A-share market has been on a volatile upward trajectory, with significant attention on whether this trend will continue into 2026 [5]. - Some institutions believe that the A-share market may reach a peak in spring 2026, with potential triggers for a comprehensive market rally [5]. - The market is expected to experience a critical verification period in 2026, with indices likely to remain volatile but on an upward trend [6]. Sector Focus - The technology, cyclical, and manufacturing sectors are highlighted as key areas of focus for 2026 [8]. - Specific recommendations include monitoring recovery trades in basic chemicals and industrial metals, as well as trends in AI, humanoid robots, energy storage, photovoltaics, pharmaceuticals, and military industries [8]. - Resource products may emerge as a new mainline direction following technology, driven by global monetary easing and domestic inventory cycles [9]. Investment Sentiment - The A-share market's current rally is significantly supported by retail investors, with a notable influx of high-risk preference funds [6]. - The upcoming five-year planning period is expected to yield positive market performance, aligning with policy directions [6].

Core Viewpoint - The article discusses the optimistic outlook for China's economy and A-share market in 2026, highlighting the potential for high-quality development and the importance of sectors such as technology, cyclical industries, and manufacturing [3][5][11]. Economic Outlook - Multiple institutions predict that China's economy will maintain resilience and enter a new phase of high-quality development in 2026, marking the beginning of the "15th Five-Year Plan" [5]. - Macro policies are expected to shift from extraordinary counter-cyclical adjustments to a more normalized approach, focusing on technological self-reliance and the cultivation of new productive forces [5]. - External demand is anticipated to remain robust, while internal demand will rely on fiscal efforts to stimulate investment in human capital and consumer supply [5]. A-share Market Trends - The A-share market has been on a rising trend since 2025, with active trading observed. There are differing opinions on whether this upward trend will continue in 2026, with some institutions expecting a comprehensive market rally while others foresee a slowdown in growth [7][8]. - By mid-2026, it is expected that the "policy bottom, market bottom, and economic bottom" will successively appear, potentially triggering a comprehensive market rally [8]. - The overall sentiment is that the A-share market's upward momentum is far from over, with expectations that it may challenge levels not seen in the past decade [8]. Sector Focus - Key sectors to watch in 2026 include technology, cyclical industries, and manufacturing, with specific attention to areas such as AI, robotics, energy storage, photovoltaics, pharmaceuticals, and military industries [11]. - Institutions suggest that resource products may emerge as a new mainline direction following technology, driven by global monetary easing, supply-demand gaps, and domestic inventory replenishment [11]. - The TMT (Technology, Media, and Telecommunications) and advanced manufacturing sectors are expected to remain central to market dynamics, with potential for significant growth [11]. Capital Flow Insights - Residents are identified as the most significant source of funds in the A-share market, with current trends resembling those seen in 2015. High-risk preference funds have entered the market rapidly, while medium-risk preference funds may represent the next incremental growth phase [9].

Core Viewpoint - Zhongke Shuguang's Q3 2025 report shows impressive performance with steady revenue growth and a significant year-on-year increase in net profit excluding non-recurring items [1] Group 1: Financial Performance - The company reported robust revenue growth and a substantial increase in net profit year-on-year [1] - The non-recurring net profit showed a high growth rate compared to the previous year [1] Group 2: Product Development - Zhongke Shuguang recently launched the scaleX640 super node, which significantly enhances single cabinet computing power density [1] - The new product supports multiple brand acceleration cards and mainstream computing ecosystems, potentially establishing a new paradigm for domestic intelligent computing [1] Group 3: Strategic Initiatives - The company is actively advancing the merger with Haiguang Information, aiming to create a leading domestic computing power industry chain [1] - The goal is to achieve deep integration and synergy from chips to services, which is expected to significantly enhance core competitiveness [1] Group 4: Investment Rating - The company maintains a "buy" rating based on its strong performance and strategic initiatives [1]

Core Viewpoint - The shareholders of Jinkai Biological Science and Technology (金凯生科) plan to reduce their holdings, which may impact the stock's performance and investor sentiment [1][2][3] Shareholder Reduction Plans - Shareholder Qilu (Xiamen) Equity Investment Partnership plans to reduce up to 3,612,000 shares, accounting for 3% of the total share capital, with a breakdown of 1,204,000 shares through centralized bidding and 2,408,000 shares through block trading [1][2] - Shareholder Qingdao Qingsong Venture Capital Group plans to reduce up to 1,204,000 shares, representing 1% of the total share capital, through centralized bidding [1][2] - Shareholder Blue Economic Zone Industrial Investment Fund plans to reduce up to 2,339,076 shares, accounting for 1.94% of the total share capital, with 1,204,000 shares through centralized bidding and 1,135,076 shares through block trading [2] Total Reduction Overview - The total planned reduction by Qilu Investment, Qingsong Investment, and Blue Zone Fund amounts to 7,155,076 shares, which is 5.94% of the total share capital [2] Current Shareholding Structure - As of the announcement date, Qilu Investment holds 5,936,580 shares (4.93%), Qingsong Investment holds 3,861,074 shares (3.21%), and Blue Zone Fund holds 2,339,076 shares (1.94%) [2] Company Background - Jinkai Biological Science and Technology was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on August 3, 2023, with an issuance of 21,508,335 shares at a price of 56.56 RMB per share [3] - The company raised a total of 1.216 billion RMB, with a net amount of approximately 1.111 billion RMB after deducting issuance costs [3] - The company plans to use the raised funds for pharmaceutical intermediates, high-end pharmaceutical products, and working capital [3] Dividend Distribution Plan - The company plans to distribute dividends at a rate of 8 RMB per 10 shares and to increase capital by 4 shares for every 10 shares held, with the record date set for May 8, 2024 [3]

2025年11月17日，中国宏桥（1378.HK）完成定价15亿美元（116.8亿港元）先旧后新配售，本项目亦为 今年以来香港资本市场第三大规模的新股配售。中信建投证券作为联席全球协调人及配售代理，助力公 司顺利完成本次发行。 来源：市场资讯 （来源：中信建投证券投行委） 中国宏桥 中信建投证券 本次基础发行规模为12亿美元，簿记启动后获得国际和国内主权基金、顶级长线基金和多策略基金热烈 追捧，最终发行规模上调至15亿美元，充分印证了市场对中国宏桥投资价值的高度认可。 坚守金融服务实体经济的根本宗旨 中信建投证券坚守金融服务实体经济的根本宗旨，依托"行业+区域+产品"的矩阵服务模式，协助中国 宏桥及下属子公司完成了多个资本运作项目，强化我国在全球有色金属产业链中的重要地位，服务客户 不断提升创新力和竞争力，书写金融助力实体经济的新篇章。 全球领先的铝产品制造商 中国宏桥是一家全球特大型铝生产企业和全球领先的铝产品制造商。公司成功构建了铝土矿、氧化铝、 电解铝及铝深加工一体化铝产业链，形成了显著的抗风险能力、成本控制能力等核心竞争力，是全球少 数几家具有完整一体化铝产业链优势的综合性铝生产、制造和销售企业。 本 ...

Core Viewpoint - The investment outlook for the pharmaceutical and bioproducts industry in 2026 indicates a potential recovery in demand and improvement in fundamentals and valuations, particularly in the traditional Chinese medicine sector [1] Group 1: Traditional Chinese Medicine - Short-term pressure from the base is expected to ease, with channel inventory clearing accelerating [1] - There is optimism for demand recovery by the end of the year, along with opportunities for fundamental and valuation improvements [1] - The brand extension space for traditional Chinese medicine consumer companies is broad, supported by innovation [1] Group 2: Blood Products - Attention is drawn to the "14th Five-Year Plan" for plasma station construction and industry consolidation progress [1] - Demand for immunoglobulin and factor products is expected to increase, along with new product development [1] Group 3: Vaccine Industry - Focus on the sales improvement of key products and the progress of innovative pipelines [1] - Policy developments and international expansion of vaccines are anticipated to further drive corporate growth [1] Group 4: Pharmaceutical Retail - The transformation and reform in the pharmaceutical retail sector are progressing steadily [1] - Future catalysts for growth are being monitored [1] Group 5: Pharmaceutical Distribution - The revenue side of the pharmaceutical distribution industry is showing steady improvement [1] - Attention is on payment collection and the "14th Five-Year Plan" [1]